LWLIVING WITH T1D
Living With T1D/October 30, 2026/3 min read

How Automated Insulin Delivery Is Changing Type 1 Diabetes Care

New research shows that systems connecting glucose monitors and insulin pumps can improve blood sugar control across different age groups and life stages. Here's what the latest evidence reveals about this technology.

Research summaryVideo report, corroborated with 6 indexed studies

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dtechnologysupport

Key takeaways

  • Automated insulin delivery systems improve time in range by about 12% compared to traditional insulin therapy, based on analysis of 65 clinical trials.
  • These systems work by automatically adjusting insulin delivery based on continuous glucose readings, though users still need training and some systems require meal announcements.
  • Older adults, pregnant women, and children all show meaningful benefits, including reduced low blood sugar events and better overall glucose control.
  • Dual-hormone fully closed-loop systems showed greater improvements than hybrid systems, though research on long-term cost-effectiveness in children is still ongoing.

What Automated Insulin Delivery Systems Do

Automated insulin delivery (AID) systems connect a continuous glucose monitor with an insulin pump and use an algorithm to automatically adjust insulin doses based on glucose readings throughout the day. The technology aims to reduce the daily burden of managing Type 1 diabetes and improve how much time a person spends in their target glucose range.

Despite their automation, these systems still require user input and training. Many systems ask users to announce meals, and people need to understand how the technology works and how to troubleshoot when needed. For many non-pregnant adults, a common glucose target is spending more than 70% of the day in range.

What the Research Shows About Glucose Control

A systematic review of 65 randomized clinical trials involving 3,623 patients found that automated insulin delivery systems increased time in range by 11.74 percentage points compared to standard insulin treatments. The systems also improved a measure called the glycemia risk index, which captures both high and low blood sugar events.

The research revealed that certain groups benefited more in some areas. People who had lived with Type 1 diabetes for more than 20 years showed more pronounced reductions in low blood sugar time. Additionally, dual-hormone fully closed-loop systems—which deliver both insulin and glucagon—showed greater improvements in time in range compared with hybrid closed-loop systems, which deliver only insulin.

Benefits for Older Adults and People at Risk for Lows

Serious low blood sugar is a particular concern for older adults with Type 1 diabetes. A trial of 82 people aged 65 to 86 tested three different insulin delivery approaches over three 12-week periods: a hybrid closed-loop system, a predictive low-glucose suspend system (which pauses insulin when lows are predicted), and a sensor-augmented pump.

The hybrid closed-loop system reduced time below 70 mg/dL by about 1 percentage point compared to the sensor-augmented pump, and time in the target range (70–180 mg/dL) improved by nearly 9 percentage points. Both automated approaches significantly lowered dangerous low blood sugar episodes in this age group.

Using Closed-Loop Systems During Pregnancy

High blood sugar during pregnancy with Type 1 diabetes raises risks for both mother and baby. A recent randomized trial called CIRCUIT tested closed-loop insulin delivery in 91 pregnant women, comparing it to standard care (insulin pump or multiple daily injections) with continuous glucose monitoring.

Women using closed-loop systems spent 65.4% of the time in the pregnancy-specific glucose range (63–140 mg/dL) between weeks 16 and 34 of pregnancy, compared to 50.3% in the standard care group—a difference of 12.5 percentage points. The closed-loop group had one episode of severe low blood sugar and two episodes of diabetic ketoacidosis, while the standard care group had one episode of ketoacidosis. These results suggest closed-loop technology can help pregnant women achieve tighter glucose control, though safety monitoring remains important.

What Questions Remain

Researchers are actively investigating the long-term impact of starting automated insulin delivery early in childhood. A currently recruiting trial in Finland is examining whether starting AID therapy soon after diagnosis in children aged 7–16 improves long-term glucose control, reduces diabetes-related stress for patients and families, and whether the higher upfront cost of AID therapy is justified by better long-term outcomes and fewer complications.

While evidence supports the benefits of automated insulin delivery across different age groups, ongoing research will help clarify which systems work best for which populations, how to optimize training and support, and how to make these technologies accessible and sustainable over a lifetime of diabetes care.

Evidence label

Origin: YouTube / ClinCurrent (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Our own writing on the same ground.

More evidence-labeled coverage across the Type1Cure library.